Skip to content

Study · Case report or series · n = 1 · 2024

1 result

An Unusual Case of an Acute Episode of Restless Leg Syndrome Following Oral Metoclopramide Therapy.

Aljunaid MA

Cureus7 Feb 2024Cited by 2 (Europe PMC)

PMID38327722 (opens in a new tab)PMCIDPMC10848601 (opens in a new tab)DOI10.7759/cureus.53754 (opens in a new tab)PepBankPUB-38327722
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

Restless leg syndrome (RLS) is a chronic disorder characterized by a compulsive urge to move the legs, accompanied by various subjective symptoms and a distinctive nyctimeral pattern. A negligent entity is drug-induced RLS, which may be challenging to recognize by practitioners due to its rarity. Among various drugs that can induce or exacerbate RLS, metoclopramide is notable; however, the literature primarily describes cases related to its intravenous forms. In this case presentation, a 33-year-old male experienced drug-related gastrointestinal (GI) symptoms after starting semaglutide for weight loss. Semaglutide was discontinued, and oral metoclopramide was administered to manage the GI symptoms. Subsequently, he developed RLS-like symptoms, which resolved within 48 hours of stopping metoclopramide. His family history included chronic RLS. Laboratory tests were normal. The case highlights a potential link between drug administration and transient RLS symptoms. This case suggests that RLS can be a rare, reversible side effect of oral metoclopramide. It emphasizes the need for careful monitoring of RLS symptoms in patients using this drug and highlights the variability of side effects depending on the method of drug administration. The case serves as a reminder of the unpredictable nature of drug reactions and the importance of vigilance in pharmacotherapy.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanCase report or seriesSafety outcome

    A 33-year-old man had drug-related gastrointestinal symptoms after starting semaglutide for weight loss, and semaglutide was discontinued.

    In plain wordsOne man had stomach and bowel symptoms after starting semaglutide for weight loss, and he stopped the drug.

    Peptide
    Semaglutide
    Outcome
    Not applicableGastrointestinal symptoms after starting semaglutide
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In this case presentation, a 33-year-old male experienced drug-related gastrointestinal (GI) symptoms after starting semaglutide for weight loss.
    1 context sentence
    Summary · context
    Semaglutide was discontinued, and oral metoclopramide was administered to manage the GI symptoms.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.